Conference abstract · 2021
Conference abstractPublished 5 Nov 2018
Novel cytotoxicity and broad-spectrum genotoxicity platforms
Massachusetts Institute of Technology, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Toxicity and Genotoxicity testing are fundamental to drug safety and drug development. Here, we leverage cell microarray technology to create a robust and highly sensitive cytotoxicity platform and a broad-spectrum genotoxicity platform. Quantification of cell viability is one of the most fundamental and broadly used endpoints in the life sciences. The gold standard is the colony forming assay. While the assay has an impressive dynamic range (over several orders of magnitude), it is relatively low-throughput (10-21days), laborious and requires large dishes/high volumes of media, thus requiring large amounts of test compounds. Microtiter cytotoxicity assay has thus been developed, including the XTT and the CellTiter-Glo assays. The XTT assay suffers from low sensitivity, and the CellTiter-Glo assay is subject to artifacts due to its indirect measure of cell viability. To overcome these limitations, we developed the MicroColonyChip (uCC) assay, which directly measures the ability of cells to divide (like the gold-standard colony forming assay), but with the scale and speed of microtiter assays. Microcolonies grow in a microarray and toxicity is derived using a novel metric, namely the change in the distribution of microcolony sizes. The result is an exquisitely sensitive assay that is robust to artifacts. For genotoxicity testing, the comet assay is a commonly used approach. We recently developed a higher throughput version of the comet assay that exploits a cell microarray. The “CometChip” is more than 1000X faster, far more sensitive and includes automated data analysis. Further, we broadened the spectrum of detectable lesions to include bulky lesions, a class of DNA damaging agents that have the potential to cause cancer. Accurate cytotoxicity and genotoxicity testing hold a central role in drug development. Having reliable and sensitive assays enables identification of untoward deleterious effects of drug candidates, providing immense savings by narrowing the candidate pool. Further, cytotoxicity and genotoxicity assays are also pivotal for the development of novel DNA damaging chemotherapeutics, the mainstay of cancer treatment today.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 12 Aug 2022
Anticarcinogenic, antimicrobial and broad-spectrum analysis of aqueous leaf extract of Citrullu colocynthis in vitro.
Conference abstract · 25 Jan 2022
Identification of a putative master regulator of disease resistance receptor proteins for enhancing broad-spectrum pathogen and pest resistance in soybean
Conference abstract · 2021
Fast-acting, broad-spectrum antimicrobial polymers to combat a growing global health concern
Research article · Sep 2014
Identification of a Broad-Spectrum Antifungal Chitinase from Bacillus Subtilis Strain BC121
More from this journal
The newest in Journal of Biotechnology & Biomaterials.
Editorial · 30 May 2025
Biocatalytic Conversion of Agricultural Waste into Value-Added Chemicals Using Engineered Microbial Systems
Editorial · 30 May 2025
3D Bioprinting of Vascularized Tissue Constructs Using Bioink-Embedded Endothelial Cells
Editorial · 30 May 2025
Development of Flexible Bioelectronic Interfaces for Real-Time Neural Signal Monitoring
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Biotechnology & Biomaterials
- SubjectBiochemistry & Biotechnology
- SubjectMaterials Science
- BylineArticles whose byline prints “Bevin Engelward”
